FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1290-1297 November 2, 2000 Number 18 Next

	Full Text PDF Editorial by O'Connor, P. G. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Opioid dependence is a chronic, relapsing disorder with important public health implications.

Methods In a 17-week randomized study of 220 patients, we compared levomethadyl acetate (75 to 115 mg), buprenorphine (16 to 32 mg), and high-dose (60 to 100 mg) and low-dose (20 mg) methadone as treatments for opioid dependence. Levomethadyl acetate and buprenorphine were administered three times a week. Methadone was administered daily. Doses were individualized except in the group assigned to low-dose methadone. Patients with poor responses to treatment were switched to methadone.

Results There were 55 patients in each group; 51 percent completed the trial. The mean (±SE) number of days that a patient remained in the study was significantly higher for those receiving levomethadyl acetate (89±6), buprenorphine (96±4), and high-dose methadone (105±4) than for those receiving low-dose methadone (70±4, P<0.001). Continued participation in the study was also significantly more frequent among patients receiving high-dose methadone than among those receiving levomethadyl acetate (P=0.02). The percentage of patients with 12 or more consecutive opioid-negative urine specimens was 36 percent in the levomethadyl acetate group, 26 percent in the buprenorphine group, 28 percent in the high-dose methadone group, and 8 percent in the low-dose methadone group (P=0.005). At the time of their last report, patients reported on a scale of 0 to 100 that their drug problem had a mean severity of 35 with levomethadyl acetate, 34 with buprenorphine, 38 with high-dose methadone, and 53 with low-dose methadone (P=0.002).

Conclusions As compared with low-dose methadone, levomethadyl acetate, buprenorphine, and high-dose methadone substantially reduce the use of illicit opioids.

Source Information

From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD 21224, where reprint requests should be addressed to Dr. Johnson.

Full Text of this Article

This article has been cited by other articles:

• Virk, M. S., Arttamangkul, S., Birdsong, W. T., Williams, J. T. (2009). Buprenorphine Is a Weak Partial Agonist That Inhibits Opioid Receptor Desensitization. J. Neurosci. 29: 7341-7348 [Abstract] [Full Text]  
• Bayoumi, A. M. MD MSc, Zaric, G. S. PhD (2008). The cost-effectiveness of Vancouver's supervised injection facility. CMAJ 179: 1143-1151 [Abstract] [Full Text]  
• Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., Forman, R., Vetter, V., McNicholas, L., Blaine, J., Lynch, K. G., Fudala, P. (2008). Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth: A Randomized Trial. JAMA 300: 2003-2011 [Abstract] [Full Text]  
• Sullivan, L. E., Fiellin, D. A. (2008). Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice. ANN INTERN MED 148: 662-670 [Abstract] [Full Text]  
• Kinlock, T. W., Gordon, M. S., Schwartz, R. P., O'Grady, K. E. (2008). A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes.. Criminal Justice and Behavior 35: 34-47 [Abstract]  
• Wedam, E. F., Bigelow, G. E., Johnson, R. E., Nuzzo, P. A., Haigney, M. C. P. (2007). QT-Interval Effects of Methadone, Levomethadyl, and Buprenorphine in a Randomized Trial. Arch Intern Med 167: 2469-2475 [Abstract] [Full Text]  
• Kakko, J., Gronbladh, L., Svanborg, K. D., von Wachenfeldt, J., Ruck, C., Rawlings, B., Nilsson, L.-H., Heilig, M. (2007). A Stepped Care Strategy Using Buprenorphine and Methadone Versus Conventional Methadone Maintenance in Heroin Dependence: A Randomized Controlled Trial. Am. J. Psychiatry 164: 797-803 [Abstract] [Full Text]  
• Gupta, S. K., Sellers, E., Somoza, E., Angles, L., Kolz, K., Cutler, D. L. (2007). The Effect of Multiple Doses of Peginterferon alfa-2b on the Steady-State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy. J Clin Pharmacol 47: 604-612 [Abstract] [Full Text]  
• Boothby, L. A., Doering, P. L. (2007). Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm 64: 266-272 [Abstract] [Full Text]  
• Tiihonen, J., Kuoppasalmi, K., Fohr, J., Tuomola, P., Kuikanmaki, O., Vorma, H., Sokero, P., Haukka, J., Meririnne, E. (2007). A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence. Am. J. Psychiatry 164: 160-162 [Abstract] [Full Text]  
• Kosten, T. R., Kosten, T. A. (2007). New Medication Strategies for Comorbid Substance Use and Bipolar Affective Disorders. Focus 5: 262-269 [Abstract] [Full Text]  
• Tomko, J. R, Giannetti, V. J (2007). Pharmacist Influence in Buprenorphine Treatment Outcomes for Opioid Dependence. The Annals of Pharmacotherapy 41: 161-161 [Full Text]  
• Kushel, M. B., Miaskowski, C. (2006). End-of-Life Care for Homeless Patients: "She Says She Is There to Help Me in Any Situation". JAMA 296: 2959-2966 [Abstract] [Full Text]  
• Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., Schottenfeld, R. S. (2006). Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.. NEJM 355: 365-374 [Abstract] [Full Text]  
• Ehret, G. B., Voide, C., Gex-Fabry, M., Chabert, J., Shah, D., Broers, B., Piguet, V., Musset, T., Gaspoz, J.-M., Perrier, A., Dayer, P., Desmeules, J. A. (2006). Drug-Induced Long QT Syndrome in Injection Drug Users Receiving Methadone: High Frequency in Hospitalized Patients and Risk Factors.. Arch Intern Med 166: 1280-1287 [Abstract] [Full Text]  
• Chang, Y., Moody, D. E., McCance-Katz, E. F. (2006). NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE. Drug Metab. Dispos. 34: 440-448 [Abstract] [Full Text]  
• Baker, J. R, Best, A. M, Pade, P. A, McCance-Katz, E. F (2006). Effect of Buprenorphine and Antiretroviral Agents on the QT Interval in Opioid-Dependent Patients. The Annals of Pharmacotherapy 40: 392-396 [Abstract] [Full Text]  
• Ciraulo, D. A., Hitzemann, R. J., Somoza, E., Knapp, C. M., Rotrosen, J., Sarid-Segal, O., Ciraulo, A. M., Greenblatt, D. J., Chiang, C. N. (2006). Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials. J Clin Pharmacol 46: 179-192 [Abstract] [Full Text]  
• O'Connor, P. G. (2005). Methods of Detoxification and Their Role in Treating Patients With Opioid Dependence. JAMA 294: 961-963 [Full Text]  
• Vocci, F. J., Acri, J., Elkashef, A. (2005). Medication Development for Addictive Disorders: The State of the Science. Am. J. Psychiatry 162: 1432-1440 [Abstract] [Full Text]  
• Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., Nielsen, D. A. (2005). Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments. Pharmacol. Rev. 57: 1-26 [Abstract] [Full Text]  
• Schottenfeld, R. S., Chawarski, M. C., Pakes, J. R., Pantalon, M. V., Carroll, K. M., Kosten, T. R. (2005). Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence. Am. J. Psychiatry 162: 340-349 [Abstract] [Full Text]  
• Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., Klingmuller, D. (2005). Plasma Testosterone and Sexual Function in Men Receiving Buprenorphine Maintenance for Opioid Dependence. J. Clin. Endocrinol. Metab. 90: 203-206 [Abstract] [Full Text]  
• Krantz, M. J., Mehler, P. S. (2004). Treating Opioid Dependence: Growing Implications for Primary Care. Arch Intern Med 164: 277-288 [Abstract] [Full Text]  
• Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., Tusel, D., the Buprenorphine/Naloxone Collaborative Study Gro, (2003). Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone. NEJM 349: 949-958 [Abstract] [Full Text]  
• Cami, J., Farre, M. (2003). Drug Addiction. NEJM 349: 975-986 [Full Text]  
• Gold, P. B., Brady, K. T. (2003). Evidence-Based Treatments for Substance Use Disorders. Focus 1: 115-122 [Abstract] [Full Text]  
• Comer, S. D., Collins, E. D. (2002). Self-Administration of Intravenous Buprenorphine and the Buprenorphine/Naloxone Combination by Recently Detoxified Heroin Abusers. J. Pharmacol. Exp. Ther. 303: 695-703 [Abstract] [Full Text]  
• Krantz, M. J., Lewkowiez, L., Hays, H., Woodroffe, M. A., Robertson, A. D., Mehler, P. S. (2002). Torsade de Pointes Associated with Very-High-Dose Methadone. ANN INTERN MED 137: 501-504 [Abstract] [Full Text]  
• Fiellin, D. A., O'Connor, P. G. (2002). Office-Based Treatment of Opioid-Dependent Patients. NEJM 347: 817-823 [Full Text]  
• Gueye, P. N., Borron, S. W., Risede, P., Monier, C., Buneaux, F., Debray, M., Baud, F. J. (2002). Buprenorphine and Midazolam Act in Combination to Depress Respiration in Rats. Toxicol Sci 65: 107-114 [Abstract] [Full Text]  
• Stimmel, B., Reese, T. V., Johnson, R. E., Strain, E. C., Bigelow, G. E., O'Connor, P. G. (2001). Treating Opioid Dependence. NEJM 344: 530-531 [Full Text]  
• (2000). New Hope for Opioid-Dependent Patients. JWatch Psychiatry 2000: 3-3 [Full Text]  
• (2000). Effective Treatments for Opioid Dependence. JWatch General 2000: 4-4 [Full Text]  
• O'Connor, P. G. (2000). Treating Opioid Dependence -- New Data and New Opportunities. NEJM 343: 1332-1334 [Full Text]